FGFR2 and cholangiocarcinoma: Zhao et al. [108] found that the protein tyrosine phosphatase PTPN9 interacts with FGFR2 to synergistically increase the efficacy of pemigatinib and inhibit CCA cell proliferation, migration and invasion by inhibiting FGFR2 Y656/657 phosphorylation.